Nicolle Wagner-Gutierrez

Nicolle Wagner-Gutierrez

Auto-generated profile, based on publicly available information

Nicolle Wagner-Gutierrez

University of North Carolina at Chapel Hill, Gillings School of Global Public Health, Chapel Hill, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2025 in Translational Lung Cancer Research
Verified
Journal Article
Open access
PDF file
ARAlejandro Ruíz-Patiño
Alejandro Ruíz-Patiño
JZJairo Zuluaga
Jairo Zuluaga
NWNicolle Wagner-Gutierrez
Nicolle Wagner-Gutierrez
OAOscar Arrieta
Oscar Arrieta
LRLeonardo Rojas
Leonardo Rojas
ACAndres Cardona
Andres Cardona
Background: Clonality is an intrinsic phenomenon of disease evolution, with specific clones conferring increased aggressiveness. We aimed to evaluated the different divergent and unique mutational patterns in brain metastases (BM). Methods: This retrospective cohort study included patients with epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma and BM. All the patients underwent three next-generation sequencing (NGS)-based genomic profiling assessments. Two analyses involved tissue samples from the lung and brain lesions, whereas the third utilized either liquid or tissue biopsy. Treatment consisted of Osimertinib and Stereotactic radiosurgery. Results: Thirty patients were included (73% female). Central nervous system (CNS) involvement was noted in 90% of the patients at diagnosis, with a median of two BM. 46% exhibited Ex19del, while the remainder had an L858R mutation. The most frequently co-mutated gene in primary lesions was TP53 (50%), followed by RBM10. All patients showed an increase in tumor mutational burden (TMB) from the primary lung lesions to the CNS metastases, rising from a median of 3.2 to 8.5 mut/Mb. Additionally, 30% of the EGFR mutations were lost. Regarding co-mutations in BM, alterations in PIK3CA/PTEN/AKT at 36%, BRAF (11%), and RB1 (13%) were presented. MET amplification was detected in 15% of cases upon systemic disease progression, while small cell transformation occurred in 7%. PIK3CA and BRAF mutations, initially found solely in BM, re-emerged in systemic disease in 16% of the cases. Conclusions: The molecular features of BM differ from those of the primary tumor. These results indicate that specific brain metastatic clones can also result in systemic progression.

31 May 2019 in ACS Applied Bio Materials
Verified
Journal Article
Closed access
KVKaren T. Valencia-Rivero
Karen T. Valencia-Rivero
Juan CruzJuan Cruz
Juan Cruz
NWNicolle Wagner-Gutierrez
Nicolle Wagner-Gutierrez
ADAntonio D’aMore
Antonio D’aMore
MMMaria C. Miranda
Maria C. Miranda
JBJuan C. Briceño
Juan C. Briceño

1 January 2025 in Case Reports in Oncological Medicine
Verified
Journal Article
Open access
VAVaneza Avila-Rodriguez
Vaneza Avila-Rodriguez
NWNicolle Wagner-Gutiérrez
Nicolle Wagner-Gutiérrez
JJJavier Jacobo
Javier Jacobo
DPDiego Pineda
Diego Pineda
AGAlejandro Gonzalez
Alejandro Gonzalez
ACAndres Cardona
Andres Cardona
Esthesioneuroblastoma (ENB), also known as olfactory neuroblastoma, is a rare neuroendocrine malignancy arising from the olfactory neuroepithelium. It exhibits a wide range of biological behaviors, from indolent to highly aggressive disease, often requiring a multimodal treatment approach involving surgical resection, radiotherapy, and chemotherapy, though outcomes remain variable. The overexpression of somatostatin receptors (SSTRs), particularly SSTR2, has led to the exploration of peptide receptor radionuclide therapy (PRRT) with lutetium‐177 DOTATATE (Lu‐177) as a targeted option in refractory cases. We present the case of a 64‐year‐old woman with recurrent, metastatic ENB, Kadish Stage D (T2N0M0G2). After undergoing surgical resection, intensity‐modulated radiotherapy (IMRT), and systemic chemotherapy (cisplatin/etoposide), the patient experienced disease progression, prompting the initiation of targeted therapy with sunitinib. Given high SSTR expression detected on Gallium‐68 PET imaging, four cycles of PRRT with Lu‐177 DOTATATE were introduced with adverse effects (Grade 1 fatigue, nausea, leukopenia, anemia, and thrombocytopenia). While initial tumor regression was observed, subsequent progression necessitated further stereotactic body radiotherapy (SBRT) and temozolomide. This case highlights the therapeutic potential of PRRT with Lu‐177 DOTATATE in treating refractory SSTR‐expressing ENB. A multidisciplinary approach that integrates surgery, radiotherapy, systemic therapy, and theragnostic strategies remains essential to optimizing patient outcomes.

1 January 2025 in JCO Global Oncology
Verified
Journal Article
Closed access
MPMilena Parra
Milena Parra
APAndrea Prada
Andrea Prada
ACAlexander Casallas
Alexander Casallas
LGLiliana Gutiérrez-Babativa
Liliana Gutiérrez-Babativa
AJAndrea Jaramillo
Andrea Jaramillo
ACAndres Cardona
Andres Cardona
PURPOSE: Cancer constitutes a significant global health challenge, with projections indicating a continued increase in its prevalence in the foreseeable future. This trend is particularly pronounced in Latin America (LATAM), where the cancer burden has increased substantially over the coming decades. Concurrently, nursing, which represents the largest segment of the health care workforce globally, is important for addressing the multifaceted challenges posed by cancer care, particularly in low- and middle-income countries (LMICs). Despite the essential role of nursing in cancer care, several barriers hinder its optimal contribution, particularly in LMICs. These challenges include professional hierarchy, insufficient educational standards, underfunding for research, and limited representation in decision-making processes. METHODS: To address these challenges, collaborative initiatives, such as the INCREASE Proposal, have emerged, aimed at fostering interdisciplinary dialogue and action in oncology nursing within LATAM. Through focused workshops and agile methodologies, the INCREASE Proposal seeks to identify barriers and formulate solutions across key areas including education, research, clinical practice, and policy implementation. RESULTS: The outcomes of the INCREASE Proposal underscore the urgent need for comprehensive strategies to strengthen oncology nursing in the LATAM. These strategies include enhancing education and recognition within health care systems, fostering interdisciplinary collaboration, leveraging advanced technologies, conducting cost-benefit analyses, and promoting research-academic partnerships. CONCLUSION: By addressing these challenges and implementing the proposed solutions, LATAM can advance toward optimized oncology nursing practice, improving cancer care delivery and outcomes across the region.

3 February 2026 in medRxiv
Verified
Preprint
Open access
PDF file
VNVíctor H Nieto
Víctor H Nieto
AAAdriana C Aya
Adriana C Aya
ACAndres Cardona
Andres Cardona
EPEdwin Pulido
Edwin Pulido
HTHeidy Trujillo
Heidy Trujillo
JNJoseph Nates
Joseph Nates
Background: Prognostic assessment in critically ill patients with cancer remains challenging, as conventional ICU severity scores often perform suboptimally in this population. Machine learning (ML) approaches may improve outcome prediction by integrating acute physiology, organ dysfunction, and oncologic variables. We aimed to develop and validate ML-based models to predict ICU mortality and 30-day survival in critically ill cancer patients. Methods: We conducted a retrospective cohort study including 997 critically ill cancer patients admitted to the ICU. Forty-eight demographic, oncologic, physiological, laboratory, and therapeutic variables collected at ICU admission were used to train and validate ML models. Eight algorithms were evaluated using stratified cross-validation with feature selection and hyperparameter optimization. Model performance was assessed using discrimination, calibration, and classification metrics. Model interpretability was explored using Shapley additive explanations (SHAP). Results: CatBoost achieved the best performance for ICU mortality prediction (AUROC 0.96), showing excellent discrimination and calibration, and outperforming other ML models. Prediction of 30-day survival was less accurate (best AUROC 0.75), reflecting the influence of post-ICU factors not captured at admission. Key predictors of ICU mortality included severity of organ dysfunction, therapeutic objectives, vasopressor and methylene blue use, SAPS III score, lactate, platelet count, and blood urea nitrogen. For 30-day survival, baseline physiological status, admission type, SAPS III, lactate, creatinine, age, and body mass index were most relevant. SHAP analysis demonstrated that acute physiology and organ dysfunction, rather than cancer diagnosis alone, primarily drove short-term outcomes. Conclusions: ML-based models, particularly CatBoost, outperformed traditional prognostic tools for predicting ICU mortality in critically ill cancer patients. Cancer was not an independent predictor of short-term mortality; outcomes were primarily driven by pre-ICU conditions, acute physiology, and severity of organ dysfunction. External validation is needed to confirm generalizability and support future integration of ML-based prediction tools into clinical decision-making in oncologic critical care.

17 February 2026 in Revista Colombiana de Hematología y Oncología
Verified
Journal Article
Open access
NWNicolle Wagner-Gutierrez
Nicolle Wagner-Gutierrez
Background: advances in molecular tumor biology have transformed oncology by enabling biomarker-driven approaches to diagnosis, prognosis, and therapy. However, integrating these innovations into routine practice depends heavily on public policy frameworks that govern test validation, reimbursement, and equitable access. Objective: this review examines international experiences with biomarker policy in oncology, evaluates the current landscape in Latin America, and proposes a roadmap for equitable adoption of molecular tumor biology in the region. Approach: a narrative review of peer-reviewed literature and authoritative policy documents was conducted. Frameworks from the United States, Canada, and the European Union were analyzed for regulatory, reimbursement, and health technology assessment (HTA) strategies. Latin American evidence was synthesized through published studies and regional reports on coverage, judicialization, and infrastructure. Results: in high-income countries, biomarker integration is supported by strong regulatory oversight, structured HTA, and reimbursement mechanisms, though access remains uneven. In Latin America, access is fragmented, with significant disparities between public and private sectors. Barriers include limited reimbursement, scarce laboratory infrastructure, workforce shortages, and the absence of standardized regulatory frameworks. Judicialization has become a common but inequitable pathway to access. Opportunities exist in leveraging regional collaborations, biobank development, and harmonized data governance. Conclusions: policy innovation is essential to ensure equitable precision oncology in Latin America. A staged roadmap is proposed that spans regulatory clarity, pilot reimbursement, workforce training, and long-term regional harmonization. Preparing for emerging technologies such as liquid biopsy and tumor-agnostic therapies will be critical to avoid widening disparities and to realize the full potential of molecular tumor biology in the region.